ArticleDiscover oncology2026
S1PR4 connects cancer pain to pan-cancer mechanisms and reveals prognosis, immune infiltration and therapeutic potential.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveSphingosine-1-phosphate receptor 4 (S1PR4), a G protein-coupled receptor predominantly expressed in immune cells, plays crucial yet complex roles in cancer biology and pain signaling. The current study was designed to evaluate its diagnostic, prognostic, and immunomodulatory roles while further exploring the molecular mechanisms underlying its dual functions in both tumor progression and pain regulation.
methodsThrough integrated analysis of TCGA, GTEx, TISIDB, GEPIA and other multi-omics databases, we performed a comprehensive pan-cancer characterization of S1PR4. We systematically evaluated the differential expression of S1PR4 between tumor and normal tissues, investigated its correlation with pain-related inflammatory molecules, and validated its expression patterns across pan-cancer cohorts. The prognostic value of S1PR4 was determined through survival analysis, while its diagnostic efficacy was assessed using ROC curve analysis. Furthermore, we characterized its association with immune subtypes and examined its correlation with immune cell infiltration. Finally, the expression profile of S1PR4 within the tumor microenvironment was verified using single-cell RNA sequencing data. We also conducted further validation of its value in BRCA.
resultsWe identified S1PR4 as a pivotal determinant of cancer pain, showing significant correlation with multiple algogenic molecules. Analysis across 24 cancer types revealed distinct dysregulation patterns, with significant diagnostic value (AUC > 0.80) in SKCM, HNSC, and THYM. Survival analysis demonstrated its protective role in most cancers except GBM, UVM, and PRAD. S1PR4 expression was enriched in immunologically active subtypes (C2/C3) and correlated specifically with CD4 + T cells, B cells, and myeloid-derived suppressor cells. Single-cell sequencing results indicated that the expression of S1PR4 was elevated in tumor cells of specific cancer types, such as GBM. In BRCA, S1PR4 coordinated an immunoregulatory network containing novel prognostic determinants.
conclusionThese findings establish S1PR4 as a multifaceted regulator of tumor immunity and cancer pain, providing a dual-targeting strategy for precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.